Acute coronary syndrome is the umbrella term for heart attacks and unstable angina — when a coronary artery suddenly narrows or closes. Treatment has evolved from emergency stenting and clot-busting drugs to rapid risk stratification, dual antiplatelet therapy, and early intervention. Most people survive, but recurrent events and heart failure remain major concerns.
What's actually going on in research
Trials are testing more targeted antiplatelet drugs, anti-inflammatory agents like colchicine and monoclonal antibodies against IL-6, drugs to protect heart muscle during a heart attack, and strategies to reduce bleeding risk while preventing clots. Studies also explore when to use imaging to guide stent placement and how to manage people with both coronary disease and atrial fibrillation.
Anti-inflammatory therapy
Colchicine, an old gout drug, is now used after heart attacks to reduce inflammation that drives future events. Trials are testing newer anti-inflammatory agents, including antibodies that block specific immune pathways.
Cardioprotection
Researchers are testing drugs and devices that limit heart muscle damage during a heart attack. The goal is to preserve more heart function and reduce the risk of heart failure afterward.
Next-generation antiplatelets
New antiplatelet drugs aim to prevent clots as effectively as current treatments but with less bleeding. Some target specific clotting pathways that may be safer to block.
What to know before you search
Eligibility typically depends on the type of acute coronary syndrome (STEMI or NSTEMI), timing since the event, treatments already received, and bleeding risk.
What types of trials are currently open
- Antiplatelet trials — Testing new drugs or dosing strategies to prevent clots without causing excessive bleeding. Often comparing combinations like aspirin plus ticagrelor or prasugrel.
- Anti-inflammatory trials — Studying drugs like colchicine or monoclonal antibodies that calm inflammation after a heart attack to reduce future cardiac events.
- Cardioprotection trials — Testing treatments given during or immediately after a heart attack to limit muscle damage and preserve heart function.
- Invasive strategy trials — Comparing timing and approach to catheterization and stenting, often using imaging to guide decisions about when and where to place stents.
- Registry studies — Tracking outcomes in large groups of people treated for acute coronary syndrome to identify what predicts recovery and complications.
Recently added Acute Coronary Syndrome trials
Common Femoral Vein-to-Artery Diameter Ratio for Detection of Elevated LVEDP
This prospective cross-sectional diagnostic accuracy study enrolled patients undergoing coronary angiography and left heart catheterization at Burapha University Hospital, Thailand. The diameters of the common femoral vein and common femoral artery were measured using ultrasonography, and the common FVD/FAD ratio was calculated. LVEDP, measured during left heart catheterization, served as the reference standard. An elevated LVEDP (\>16 mmHg) was defined as volume overload. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis.
Take a daily aspirin dose after receiving a heart stent
This is a randomized, open-label, active-controlled, non-inferiority clinical trial (the ASPIRE-LD trial) conducted in China. It aims to compare the efficacy and safety of low-dose aspirin (50 mg once daily) versus standard-dose aspirin (100 mg once daily), both in combination with a P2Y12 inhibitor, in patients who have successfully undergone percutaneous coronary intervention (PCI) and plan to receive at least 12 months of dual antiplatelet therapy (DAPT). A total of 2640 eligible patients will be randomly assigned in a 1:1 ratio to receive either 50 mg or 100 mg of enteric-coated aspirin daily, plus a P2Y12 inhibitor (ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily, prescribed according to routine clinical practice). All participants will be followed for 12 months after randomization. The primary goal is to verify that 50 mg aspirin is non-inferior to the 100 mg standard dose in preventing major adverse cardiac and cerebrovascular events (MACCE: cardiovascular death, non-fatal myocardial infarction, definite/probable stent thrombosis, and ischemic stroke) at 12 months post-PCI. If non-inferiority is confirmed, the study will further test whether 50 mg aspirin reduces clinically relevant bleeding events (BARC type 2, 3, or 5) better than the standard dose. The study is sponsored by the First Hospital of Jilin University and will be carried out in 10-15 tertiary hospitals across China. Its findings will provide evidence for optimizing aspirin dosing in post-PCI DAPT.
Find Acute Coronary Syndrome trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.